Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  bortezomib
Find trials that include:  Any drugs shown
Results 1-25 of 55 for your search:
Start Over
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AB06002, NCI-2013-00616, NCT01470131
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CC-4047-MM-007, NCI-2013-00024, NCT01734928
Bortezomib or Carfilzomib with Lenalidomide and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: E1A11, NCI-2012-02608, ECOG-E1A11, NCT01863550
Combination Chemotherapy with or without Bortezomib in Treating Younger Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: AALL1231, NCI-2014-00712, NCT02112916
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR103995, NCI-2014-02437, 2014-000255-85, 54767414MMY3004, NCT02136134
Plerixafor and Bortezomib in Treating Patients with Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 08-273, NCI-2009-01123, NCT00903968
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MM08-141, NCI-2012-00848, NCT01177683
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACY-100, NCI-2011-03019, NCT01323751
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TH-CR-408, NCI-2012-00508, NCT01522872
Sorafenib, Vorinostat, and Bortezomib in Treating Patients With Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IUCRO-0327, NCI-2012-00200, NCT01534260
Bortezomib, Dexamethasone, and Lenalidomide with or without Elotuzumab in Treating Patients with Newly Diagnosed High-Risk Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: S1211, NCI-2012-01998, CDR0000738512, PS1211_A12PAMDREVW01, SWOG-S1211, NCT01668719
A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PMHOSI906-MM001, NCI-2014-02003, NCT01672736
Bortezomib, Rituximab, and Combination Chemotherapy Followed By Maintenance Bortezomib or Observation in Treating Patients with Previously Untreated Mantle Cell Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 05-C-0170, NCI-2013-01594, NCT00131976, P6450, NCI-05-C-0170, NCI-6450, NCT00114738
Low-Dose Bortezomib in Preventing Bone Formation in Patients With Smoldering Multiple Myeloma
Phase: Phase II
Type: Prevention
Age: 18 and over
Trial IDs: HCI33979, NCI-2010-02379, NCT00983346
Bortezomib and Vorinostat as Maintenance Therapy after Autologous Stem Cell Transplant in Treating Patients with Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2292.00, NCI-2009-01302, 2292, FH 2292/X05287, X05287, NCT00992446
Bortezomib and Rituximab in Treating Patients with Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 10137, NCI-2010-02343, 109117, 118601, X05337, NCT01267812
Ofatumumab and Bendamustine Hydrochloride with or without Bortezomib in Treating Patients with Untreated Follicular Non-Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CALGB 50904, NCI-2011-02625, CDR0000694298, NCT01286272
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Patients with Previously Untreated Mantle Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 60 and over
Trial IDs: E1411, NCI-2011-02980, CDR0000707057, ECOG-E1411, NCT01415752
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 72
Trial IDs: 11-12-434, NCI-2013-01207, 11-102, NCT01605032
Bortezomib and Combination Chemotherapy Followed by Bortezomib and Lenalidomide in Treating Patients with Newly Diagnosed Multiple Myeloma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: X05397, NCI-2013-00475, Pro00038924, NCT01729338
Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Age: 18 to 80
Trial IDs: UCDCC#230, NCI-2014-00564, 322070-12, X05385, NCT01736943
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HEMALL0008, NCI-2012-03094, 25596, NCT01769209
Lenalidomide, Bortezomib, and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: 12-498, NCI-2013-01107, X05386, NCT01782963
Start Over